Skip Navigation

Annals of Oncology 2009 20(Supplement 4):iv46-iv48; doi:10.1093/annonc/mdp125
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Eckel, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Eckel, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

ESMO clinical recommendations

Biliary cancer: ESMO Clinical Recommendation for diagnosis, treatment and follow-up

F. Eckel1, S. Jelic2 and On behalf of the ESMO Guidelines Working Group*

1 Department of Internal Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany
2 Internal Medicine Service, Institute of Oncology and Radiology, Belgrade, Serbia

* Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland; E-mail: clinicalrecommendations@esmo.org

The first 10% of the full text of this article appears below.


   incidence
 
The crude incidence of gallbladder and extrahepatic biliary cancer (ICD-10:C23-C24) in the European Union is ~3.2 and ~5.4/100 000 per year for males and females, respectively. Age-adjusted mortality is 1.4 and 1.9/100 000 for males and females, respectively. Incidence of intrahepatic cholangiocarcinoma (ICD-10:C22.1) is increasing and may be estimated as ~0.9–1.3 and 0.4–0.7/100 000 for males and females, respectively, as 10–15% of primary liver cancer (ICD-10:C22). In high risk areas in Europe (south Italy) incidence is estimated up to ~4.9–7.4 and ~2.9–4.3/100 . . . [Full Text of this Article]


   diagnosis
 

   staging
 

   treatment after incidental finding of gallbladder cancer on pathologic review
 

   treatment after incidental finding of gallbladder cancer at surgery
 

   treatment of resectable tumors
 

   treatment of unresectable tumors
 

   response evaluation
 

   follow-up
 

   note
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?